- Home
- RGC vs TECH Comparison
RGC vs TECH Comparison
Compare RGC & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | TECH |
|---|---|---|
| Founded | 2014 | 1976 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.2B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RGC | TECH |
|---|---|---|
| Price | $29.85 | $53.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $73.09 |
| AVG Volume (30 Days) | 153.8K | ★ 2.1M |
| Earning Date | 10-31-2025 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | N/A | ★ $1,219,635,000.00 |
| Revenue This Year | N/A | $2.49 |
| Revenue Next Year | N/A | $6.40 |
| P/E Ratio | ★ N/A | $109.16 |
| Revenue Growth | N/A | ★ 5.23 |
| 52 Week Low | $9.39 | $46.02 |
| 52 Week High | $950.00 | $72.16 |
Technical Indicators
Market Signals| Indicator | RGC | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 47.05 |
| Support Level | $12.29 | $49.30 |
| Resistance Level | $36.75 | $54.08 |
| Average True Range (ATR) | 3.89 | 2.13 |
| MACD | 0.77 | 0.56 |
| Stochastic Oscillator | 42.66 | 77.06 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.